Tarsus Pharmaceuticals Analyst Ratings
Tarsus Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/20/2023 | 0.74% | Goldman Sachs | → $19 | Initiates Coverage On | → Neutral |
| 11/10/2023 | 165.11% | HC Wainwright & Co. | $42 → $50 | Maintains | Buy |
| 09/11/2023 | 159.81% | Guggenheim | $46 → $49 | Maintains | Buy |
| 08/14/2023 | 143.9% | Guggenheim | → $46 | Reiterates | Buy → Buy |
| 08/11/2023 | 122.69% | HC Wainwright & Co. | $50 → $42 | Maintains | Buy |
| 07/26/2023 | 165.11% | HC Wainwright & Co. | $44 → $50 | Maintains | Buy |
| 07/18/2023 | 133.3% | William Blair | → $44 | Initiates Coverage On | → Outperform |
| 06/26/2023 | 133.3% | HC Wainwright & Co. | $40 → $44 | Maintains | Buy |
| 06/16/2023 | 122.69% | Guggenheim | $40 → $42 | Maintains | Buy |
| 05/18/2023 | — | Guggenheim | Initiates Coverage On | → Buy | |
| 05/08/2023 | 128% | Oppenheimer | → $43 | Reiterates | → Outperform |
| 03/15/2023 | 112.09% | HC Wainwright & Co. | → $40 | Reiterates | → Buy |
| 08/01/2022 | 112.09% | Barclays | → $40 | Initiates Coverage On | → Overweight |
| 12/21/2021 | 112.09% | HC Wainwright & Co. | → $40 | Initiates Coverage On | → Buy |
| 11/23/2021 | 191.62% | Oppenheimer | → $55 | Initiates Coverage On | → Outperform |
| 10/08/2021 | 244.64% | Raymond James | $50 → $65 | Maintains | Strong Buy |
| 06/29/2021 | 165.11% | Raymond James | $39 → $50 | Maintains | Strong Buy |
| 11/10/2020 | 122.69% | Ladenburg Thalmann | → $42 | Initiates Coverage On | → Buy |
| 11/10/2020 | 74.97% | B of A Securities | → $33 | Initiates Coverage On | → Buy |
| 11/10/2020 | 85.58% | Jefferies | → $35 | Initiates Coverage On | → Buy |
| 11/10/2020 | 106.79% | Raymond James | → $39 | Initiates Coverage On | → Strong Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/20/2023 | 0.74% | 高盛 | → 19 美元 | 啓動覆蓋範圍開啓 | → 中立 |
| 11/10/2023 | 165.11% | HC Wainwright & Co. | 42 美元 → 50 美元 | 維護 | 買 |
| 09/11/2023 | 159.81% | 古根海姆 | 46 美元 → 49 美元 | 維護 | 買 |
| 08/14/2023 | 143.9% | 古根海姆 | → 46 美元 | 重申 | 購買 → 購買 |
| 08/11/2023 | 122.69% | HC Wainwright & Co. | 50 美元 → 42 美元 | 維護 | 買 |
| 07/26/2023 | 165.11% | HC Wainwright & Co. | 44 美元 → 50 美元 | 維護 | 買 |
| 07/18/2023 | 133.3% | 威廉布萊爾 | → 44 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 06/26/2023 | 133.3% | HC Wainwright & Co. | 40 美元 → 44 美元 | 維護 | 買 |
| 06/16/2023 | 122.69% | 古根海姆 | 40 美元 → 42 美元 | 維護 | 買 |
| 05/18/2023 | — | 古根海姆 | 啓動覆蓋範圍開啓 | → 購買 | |
| 05/08/2023 | 128% | 奧本海默 | → 43 美元 | 重申 | → 跑贏大盤 |
| 03/15/2023 | 112.09% | HC Wainwright & Co. | → 40 美元 | 重申 | → 購買 |
| 08/01/2022 | 112.09% | 巴克萊 | → 40 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 12/21/2021 | 112.09% | HC Wainwright & Co. | → 40 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 11/23/2021 | 191.62% | 奧本海默 | → 55 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2021 年 8 月 10 日 | 244.64% | 雷蒙德·詹姆 | 50 美元 → 65 美元 | 維護 | 強勢買入 |
| 06/29/2021 | 165.11% | 雷蒙德·詹姆 | 39 美元 → 50 美元 | 維護 | 強勢買入 |
| 11/10/2020 | 122.69% | 拉登堡塔爾曼 | → 42 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 11/10/2020 | 74.97% | B of A 類證券 | → 33 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 11/10/2020 | 85.58% | 傑富瑞集團 | → 35 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 11/10/2020 | 106.79% | 雷蒙德·詹姆 | → 39 美元 | 啓動覆蓋範圍開啓 | → 強勢買入 |
What is the target price for Tarsus Pharmaceuticals (TARS)?
Tarsus Pharmicals（TARS）的目標價格是多少？
The latest price target for Tarsus Pharmaceuticals (NASDAQ: TARS) was reported by Goldman Sachs on November 20, 2023. The analyst firm set a price target for $19.00 expecting TARS to rise to within 12 months (a possible 0.74% upside). 12 analyst firms have reported ratings in the last year.
高盛於2023年11月20日公佈了塔蘇斯製藥（納斯達克股票代碼：TARS）的最新目標股價。該分析公司將目標股價定爲19.00美元，預計TARS將在12個月內升至12個月內（可能上漲0.74％）。去年有12家分析公司公佈了評級。
What is the most recent analyst rating for Tarsus Pharmaceuticals (TARS)?
Tarsus Pharmicals（TARS）的最新分析師評級是多少？
The latest analyst rating for Tarsus Pharmaceuticals (NASDAQ: TARS) was provided by Goldman Sachs, and Tarsus Pharmaceuticals initiated their neutral rating.
塔蘇斯製藥（納斯達克股票代碼：TARS）的最新分析師評級由高盛提供，塔蘇斯製藥啓動了中性評級。
When is the next analyst rating going to be posted or updated for Tarsus Pharmaceuticals (TARS)?
Tarsus Pharmicals（TARS）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tarsus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tarsus Pharmaceuticals was filed on November 20, 2023 so you should expect the next rating to be made available sometime around November 20, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與塔蘇斯製藥公司的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。塔蘇斯製藥的最新評級是在2023年11月20日公佈的，因此您應該預計下一個評級將在2024年11月20日左右公佈。
Is the Analyst Rating Tarsus Pharmaceuticals (TARS) correct?
分析師對Tarsus Pharmicals（TARS）的評級正確嗎？
While ratings are subjective and will change, the latest Tarsus Pharmaceuticals (TARS) rating was a initiated with a price target of $0.00 to $19.00. The current price Tarsus Pharmaceuticals (TARS) is trading at is $18.86, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但塔蘇斯製藥（TARS）的最新評級是啓動的，目標股價爲0.00美元至19.00美元。塔蘇斯製藥（TARS）目前的交易價格爲18.86美元，在分析師的預測區間內。